Pay in 4 interest-free payments of $7.05 Learn more
Ships within 48 hours · Estimated delivery Aug 27 - Sep 1
Given the limitations of conventional cancer drugs, which can be cytotoxic and non-specific, decided to investigate the potential anticancer effects of the antidiabetic drug sitagliptin, which has recently shown promise as an anticancer agent and is known for its good tolerability and efficacy
We propose a unifying framework in which CYP51A1 integrates metabolic reprogramming and cell fate control, highlighting its potential as a therapeutic target across diverse human diseases
Fair Use & Trademark Acknowledgment All product names, logos, brands, and trademarks featured in this article are the property of their respective owners
Endpoint heterogeneity
US$ 21.10
US$ 22.36
US$ 26.35
US$ 26.98
US$ 23.43
